<MedlineCitation Status="Completed">
<MedlineID>10011971</MedlineID>
<PMID>283880</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0008-543X</ISSN>
<JournalIssue>
<Volume>43</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Management of asparaginase induced hemorrhagic pancreatitis complicated by pseudocyst.</ArticleTitle>
<Pagination>
<MedlinePgn>718-22</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Asparaginase induced hemorrhagic pancreatitis is a rare but serious development occurring in less than 0.5% of patients treated with this drug. Severe pancreatitis with progressive abdominal distention, toxemia, hypotension and respiratory insufficiency occurred in an 18-year-old patient with acute lymphoblastic leukemia following treatment with asparaginase. There was a dramatic response to high flow peritoneal lavage with rapid recovery within 24 hours from a moribund state. The subsequent development of a pseudocyst, with progressive increase in size and development of obstructive symptoms, required surgical decompression. Transgastric cystogastrostomy was successfully carried out.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Greenstein</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
<Author>
<LastName>Nogeire</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author>
<LastName>Ohnuma</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author>
<LastName>Greenstein</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>UNITED STATES</Country>
<MedlineTA>Cancer</MedlineTA>
<NlmUniqueID>0374236</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>EC 3.5.1.1</RegistryNumber>
<NameOfSubstance>Asparaginase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adolescence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Asparaginase</DescriptorName>
<QualifierName MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Case Report</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hemorrhage</DescriptorName>
<QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName>complications</QualifierName>
<QualifierName>therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Leukemia, Lymphocytic</DescriptorName>
<QualifierName>drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Pancreatic Cyst</DescriptorName>
<QualifierName MajorTopicYN="Y">complications</QualifierName>
<QualifierName>etiology</QualifierName>
<QualifierName>surgery</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Pancreatitis</DescriptorName>
<QualifierName MajorTopicYN="Y">chemically induced</QualifierName>
<QualifierName>complications</QualifierName>
<QualifierName>therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Peritoneal Dialysis</DescriptorName>
<QualifierName>adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
